KR100669578B1 - 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 - Google Patents

2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 Download PDF

Info

Publication number
KR100669578B1
KR100669578B1 KR1020047011276A KR20047011276A KR100669578B1 KR 100669578 B1 KR100669578 B1 KR 100669578B1 KR 1020047011276 A KR1020047011276 A KR 1020047011276A KR 20047011276 A KR20047011276 A KR 20047011276A KR 100669578 B1 KR100669578 B1 KR 100669578B1
Authority
KR
South Korea
Prior art keywords
pyrido
cyclopentyl
ylamino
pyridin
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047011276A
Other languages
English (en)
Korean (ko)
Other versions
KR20040077759A (ko
Inventor
바비안마크로버트
부쓰리차드존
퀸존3세
레핀조셉토마스
쉬한데릭제임스
투굿피터로렌스
반데르웰스코트노르만
주하이롱
Original Assignee
워너-램버트 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27613435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100669578(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 워너-램버트 캄파니 엘엘씨 filed Critical 워너-램버트 캄파니 엘엘씨
Publication of KR20040077759A publication Critical patent/KR20040077759A/ko
Application granted granted Critical
Publication of KR100669578B1 publication Critical patent/KR100669578B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
KR1020047011276A 2002-01-22 2003-01-10 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 Expired - Lifetime KR100669578B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35087702P 2002-01-22 2002-01-22
US60/350,877 2002-01-22
PCT/IB2003/000059 WO2003062236A1 (en) 2002-01-22 2003-01-10 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067018532A Division KR20060111716A (ko) 2002-01-22 2003-01-10 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온

Publications (2)

Publication Number Publication Date
KR20040077759A KR20040077759A (ko) 2004-09-06
KR100669578B1 true KR100669578B1 (ko) 2007-01-15

Family

ID=27613435

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047011276A Expired - Lifetime KR100669578B1 (ko) 2002-01-22 2003-01-10 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
KR1020067018532A Withdrawn KR20060111716A (ko) 2002-01-22 2003-01-10 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067018532A Withdrawn KR20060111716A (ko) 2002-01-22 2003-01-10 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온

Country Status (52)

Country Link
US (4) US6936612B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1470124B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4291696B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100669578B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN101906104B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP1767A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR038814A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE314370T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003237009B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2017C005I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR122016021801B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2473026C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5700765A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20120129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1105686T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60303009T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1470124T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2003000561A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA007395B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (2) ECSP045201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2251677T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR17C1012I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20063909B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT200300005A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HN (1) HN2003000039A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20040660B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUS1700009I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL162721A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2423B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1470124I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA27166A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00230B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04005939A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY134818A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NI (1) NI200300008A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300863I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO329350B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ534069A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA12755A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8563701A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20030975A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL218692B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS51044B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1470124T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV2004001459A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN04126A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI343920B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA79444C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY27617A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003062236A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200404840B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (322)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
DK1417207T3 (da) * 2000-08-04 2005-12-27 Warner Lambert Co Fremgangsmåde til fremstilling af 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-oner
JP2004505974A (ja) * 2000-08-04 2004-02-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 2−(4−ピリジル)アミノ−6−ジアルキルオキシフェニルピリド〔2,3−d〕ピリミジン−7−オン類の製造方法
HRP20030624B1 (en) * 2001-02-12 2007-03-31 F. Hoffmann - La Roche Ag 6-substituted pyrido-pyrimidines
KR100540623B1 (ko) * 2001-02-26 2006-01-11 다나베 세이야꾸 가부시키가이샤 피리도피리미딘 또는 나프틸리딘 유도체
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
CA2492112A1 (en) 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
KR100864393B1 (ko) 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 피리미도 화합물
DE602004017474D1 (de) * 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AU2004261250B2 (en) 2003-07-29 2009-02-26 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
WO2005047284A1 (en) * 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7968557B2 (en) * 2004-02-14 2011-06-28 Novartis Ag Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
EP1718645A1 (en) * 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CA2727841A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2, 3-d] pyrimidine derivatives and related compounds
WO2006053043A2 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
KR101346886B1 (ko) * 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
JP2008528469A (ja) * 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US20080161251A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006090853A1 (ja) 2005-02-25 2006-08-31 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
AR053346A1 (es) * 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
PE20100741A1 (es) * 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
EP1879573B1 (en) 2005-05-10 2012-12-19 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
KR100734837B1 (ko) * 2005-09-16 2007-07-03 한국전자통신연구원 다중 생체 인식 시스템 및 그 방법
EP1931667A1 (en) * 2005-09-28 2008-06-18 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
ES2432046T3 (es) * 2005-10-07 2013-11-29 Exelixis, Inc. Piridopirimidinonas inhibidoras de PI3Kalfa
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
JP2009536186A (ja) * 2006-05-08 2009-10-08 アステックス・セラピューティクス・リミテッド 癌処置のためのジアゾール誘導体の医薬組合せ
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
CA2662768A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
CA2665384A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
CN101535308A (zh) * 2006-11-09 2009-09-16 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的取代的6-苯基-吡啶并[2,3-d]嘧啶-7-酮衍生物及其使用方法
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2008307516B2 (en) 2007-10-05 2011-11-17 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
MY171866A (en) 2008-07-08 2019-11-05 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
MY150560A (en) * 2008-08-22 2014-01-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
CN102231983A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
CN107935983A (zh) 2008-10-03 2018-04-20 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
ES2552386T3 (es) 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
EP2429566B1 (en) 2009-05-13 2016-01-06 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
EP2474540A4 (en) * 2009-08-31 2013-03-13 Nippon Chemiphar Co GPR119 AGONIST
AU2010303218A1 (en) * 2009-10-09 2012-05-10 Afraxis Holdings, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EA201290210A1 (ru) 2009-11-06 2012-10-30 Плексксикон, Инк. Соединения и способы модуляции киназы и показания для их применения
JP5797664B2 (ja) * 2009-12-18 2015-10-21 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションTemple University−Of The Commonwealth System Of Higher Education 置換ピリド[2,3−d]ピリミジン−7(8H)−オン及びそれらの治療用の使用
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
KR101830455B1 (ko) 2010-04-13 2018-02-20 노파르티스 아게 시클린 의존성 키나제 4 또는 시클린 의존성 키나제 (cdk4/6) 억제제 및 mtor 억제제를 포함하는 암 치료를 위한 조합물
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
EP2580217A4 (en) * 2010-06-10 2014-06-18 Afraxis Holdings Inc 6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
BR112013002375B1 (pt) 2010-08-05 2020-05-12 Temple University - Of The Commonwealth System Of Higher Education Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto
CA2815084C (en) 2010-10-25 2017-05-09 G1 Therapeutics, Inc. Cdk inhibitors
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
AU2011329763A1 (en) 2010-11-17 2013-05-09 Brigham And Women's Hospital Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
SMT201900112T1 (it) 2011-02-07 2019-02-28 Plexxikon Inc Composti e metodi per la modulazione della chinasi, e indicazioni corrispettive
EP2688887B1 (en) * 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JP2014522396A (ja) 2011-05-27 2014-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 置換2−ベンジリデン−2H−ベンゾ[b][1,4]チアジン−3(4H)−オン、その誘導体及びその治療上の使用
KR20140138910A (ko) * 2012-03-14 2014-12-04 루핀 리미티드 헤테로사이클릴 화합물
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
RU2679130C2 (ru) 2012-07-11 2019-02-06 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AU2013302519B2 (en) 2012-08-17 2017-11-02 Concert Pharmaceuticals, Inc. Deuterated baricitinib
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
ES2694787T3 (es) * 2013-02-21 2018-12-27 Pfizer Inc. Formas sólidas de un inhibidor selectivo de CDK4/6
EA032094B1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
EP2968291B1 (en) 2013-03-15 2025-04-16 Pharmacosmos Holding A/S Hspc-sparing treatments for rb-positive abnormal cellular proliferation
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
CN104470921B (zh) * 2013-05-17 2017-05-03 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
MX2016005297A (es) 2013-10-25 2016-08-12 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos.
EP4512480A3 (en) * 2013-12-20 2025-05-07 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
ES2687477T3 (es) 2013-12-31 2018-10-25 Xuanzhu Pharma Co., Ltd. Inhibidor de quinasa y su uso
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US20150297608A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
ES2873959T3 (es) 2014-05-28 2021-11-04 Piramal Entpr Ltd Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
KR20170031241A (ko) * 2014-07-24 2017-03-20 베타 파마, 인크. 시클린-의존성 키나제 (cdk) 억제제로서의 2-h-인다졸 유도체 및 그의 치료적 용도
AU2015296322B2 (en) * 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
US20170217962A1 (en) * 2014-07-31 2017-08-03 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
WO2016024232A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
US20170240543A1 (en) * 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
PL3218005T3 (pl) 2014-11-12 2023-05-02 Seagen Inc. Związki oddziałujące z glikanami i sposoby ich zastosowania
CN104447743B (zh) 2014-11-26 2016-03-02 苏州明锐医药科技有限公司 帕博西尼的制备方法
CN104496983B (zh) * 2014-11-26 2016-06-08 苏州明锐医药科技有限公司 一种帕博西尼的制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
JP6581197B2 (ja) 2014-12-31 2019-09-25 深▲セン▼市薬欣生物科技有限公司Shenzhen Pharmacin Co., Ltd. 医薬組成物及びその製造方法
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
TWI690533B (zh) 2015-02-12 2020-04-11 南北兄弟藥業投資有限公司 Cdk類小分子抑制劑的化合物及其用途
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN106795159B (zh) * 2015-04-22 2018-12-28 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
JP6400196B2 (ja) * 2015-05-29 2018-10-03 帝人ファーマ株式会社 ピリド[3,4−d]ピリミジン誘導体及びその薬学的に許容される塩
PE20180395A1 (es) 2015-06-04 2018-02-28 Pfizer Formas de dosificacion solidas de palbociclib
CN104892604B (zh) * 2015-06-19 2016-08-24 北京康立生医药技术开发有限公司 一种cdk4抑制剂的合成方法
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
EP3331881B1 (en) 2015-08-05 2019-05-15 ratiopharm GmbH New crystalline form and acetic acid adducts of palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN108699055B (zh) * 2015-12-13 2020-10-23 杭州英创医药科技有限公司 用作抗癌药物的杂环化合物
US10662186B2 (en) 2015-12-31 2020-05-26 Shanghai Pharmaceuticals Holding Co., Ltd. Substituted pyrimidines as cyclin-dependent kinase inhibitors
CN105418609B (zh) * 2015-12-31 2017-06-23 山东大学 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
CN106967061A (zh) * 2016-01-13 2017-07-21 常州方楠医药技术有限公司 帕博西林的盐、晶型及其制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107266421B (zh) * 2016-04-08 2020-12-04 正大天晴药业集团股份有限公司 取代的苯并咪唑类衍生物
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
CN105949189B (zh) * 2016-06-05 2017-09-22 童明琼 一种用于治疗乳腺癌的帕博西尼的制备方法
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
US10807978B2 (en) 2016-07-04 2020-10-20 Dr. Reddy's Laboratories Limited Process for preparation of palbociclib
US10597393B2 (en) 2016-07-07 2020-03-24 Plantex Ltd. Solid state forms of Palbociclib dimesylate
PT3497103T (pt) * 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6
IL264950B2 (en) 2016-08-23 2024-01-01 Eisai R&D Man Co Ltd Combined treatments for the treatment of malignant liver cell carcinoma
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
US10710999B2 (en) 2016-10-07 2020-07-14 Mylan Laboratories Limited Polymorph of an intermediate for palbociclib synthesis
EP3804724B1 (en) 2016-10-20 2022-12-07 Pfizer Inc. Cdk inhibitors for treating pah
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
CN106565707B (zh) * 2016-11-03 2019-01-04 杭州科巢生物科技有限公司 帕博西尼新合成方法
EP3538148A1 (en) 2016-11-08 2019-09-18 Dana-Farber Cancer Institute Compositions and methods of modulating anti-tumor immunity
WO2018091999A1 (en) 2016-11-16 2018-05-24 Pfizer Inc. Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
LT3546456T (lt) * 2016-11-28 2022-03-10 Teijin Pharma Limited Pirido[3,4-d]pirimidino dariniai arba jo solvato kristalas
CA3043561A1 (en) 2016-11-28 2018-05-31 Teijin Pharma Limited Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
WO2018108167A1 (zh) 2016-12-16 2018-06-21 基石药业 Cdk4/6抑制剂
IL267795B2 (en) 2017-01-06 2023-02-01 G1 Therapeutics Inc Combination therapy for the treatment of cancer
CN108191857B (zh) * 2017-01-24 2020-10-23 晟科药业(江苏)有限公司 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
US10729692B2 (en) * 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
EP3589634A4 (en) * 2017-03-03 2020-08-12 Auckland Uniservices Limited KINASE FGFR INHIBITORS AND PHARMACEUTICAL USES
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA3056701A1 (en) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
CN108658855A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种含氮双环化合物及其制备方法和用途
CN108658854A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种生物碱化合物及其制备方法和作为海洋防污剂的应用
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2019015177A (es) 2017-06-16 2020-02-07 Beta Pharma Inc Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
CA3067873A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of g1t38 and methods of manufacture thereof
EA036060B1 (ru) * 2017-07-17 2020-09-21 Пфайзер Инк. Пиридопиримидиноновые ингибиторы cdk2/4/6
WO2019020715A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
CN109384767B (zh) * 2017-08-08 2020-05-05 江苏恒瑞医药股份有限公司 一种吡啶并嘧啶类衍生物的制备方法及其中间体
EP3676404B1 (en) 2017-08-31 2025-09-03 Novartis AG Methods of selecting a treatment for breast cancer patients
CN107488175A (zh) * 2017-09-04 2017-12-19 上海微巨实业有限公司 一种帕博西林关键中间体的制备方法
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CA3085366A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
MX2020007959A (es) 2018-01-29 2020-09-18 Beta Pharma Inc Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos.
CN108218861B (zh) * 2018-02-05 2019-07-23 黑龙江中医药大学 一种预防和治疗糖尿病的药物及其制备方法
CA3090493A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
US20200405809A1 (en) 2018-02-27 2020-12-31 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
FI3788047T3 (fi) 2018-05-04 2024-11-02 Incyte Corp Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Fgfr阻害剤の塩
ES2968899T3 (es) 2018-05-14 2024-05-14 Pfizer Formulación de la solución oral
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
PL3802529T3 (pl) 2018-05-24 2024-03-25 Synthon B.V. Sposób wytwarzania palbocyklibu
CR20240054A (es) 2018-07-05 2024-02-26 Incyte Corp DERIVADOS DE PIRAZINA FUSIONADOS COMO INHIBIDORES DE A2A/A2B (Div. 2021-71)
KR20210035211A (ko) 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
EP3840756A4 (en) 2018-08-24 2022-04-27 G1 Therapeutics, Inc. IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ
JP2022504388A (ja) 2018-10-08 2022-01-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Pi3kアルファ阻害剤およびメトホルミンを用いたがんの処置方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020114519A1 (zh) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
AU2019413360B2 (en) 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
CA3130210A1 (en) * 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3141452A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
CN112010844B (zh) * 2019-05-31 2023-07-25 中国药科大学 N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN113993505B (zh) * 2019-06-20 2023-12-12 江苏恒瑞医药股份有限公司 一种药物组合物以及其制备方法
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
EP3993785A4 (en) 2019-07-07 2023-08-02 Olema Pharmaceuticals, Inc. ESTROGEN RECEPTOR ANTAGONIST SCHEMES
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022543062A (ja) 2019-08-01 2022-10-07 インサイト・コーポレイション Ido阻害剤の投与レジメン
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
EP4069218A1 (en) 2019-12-03 2022-10-12 Genentech, Inc. Combination therapies for treatment of breast cancer
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CN114901666B (zh) 2019-12-16 2025-01-14 卢内拉生物技术有限公司 选择性cdk4/6抑制剂型癌症治疗药物
IL293932A (en) * 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cdk4/6 inhibitor cancer therapeutics
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
WO2021183994A1 (en) * 2020-03-13 2021-09-16 Prosenestar Llc Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors
CN114245753A (zh) * 2020-03-27 2022-03-25 江苏康宁杰瑞生物制药有限公司 用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
BR112022020841A2 (pt) 2020-04-16 2023-05-02 Incyte Corp Inibidores de kras tricíclicos fundidos
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
CA3173678A1 (en) 2020-05-19 2021-11-25 Jay Copeland Strum Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US20230132667A1 (en) * 2020-05-28 2023-05-04 University Of Washington Drug-like molecules and methods for the therapeutic targeting of viral rna structures
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113880809B (zh) 2020-07-03 2022-10-18 盛世泰科生物医药技术(苏州)有限公司 一种嘧啶类衍生物及其制备方法和应用
EP4181920B1 (en) 2020-07-15 2025-09-10 Pfizer Inc. Kat6 inhibitor and combinations for breast cancer treatment
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022063119A1 (zh) * 2020-09-24 2022-03-31 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112569361B (zh) * 2020-12-30 2023-01-10 扬子江药业集团上海海尼药业有限公司 一种哌柏西利干混悬组合物及其制备方法
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
KR20240021239A (ko) * 2021-06-09 2024-02-16 티와이케이 메디슨즈, 인코포레이티드 Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Krasの阻害剤としての三環式化合物
MX2024001266A (es) 2021-07-26 2024-04-16 Celcuity Inc 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
JP2024534187A (ja) 2021-08-31 2024-09-18 インサイト・コーポレイション Krasの阻害剤としてのナフチリジン化合物
CN113683612B (zh) * 2021-09-07 2022-06-17 山东铂源药业股份有限公司 一种帕布昔利布的制备方法
CN118119393A (zh) * 2021-09-14 2024-05-31 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras
TW202320792A (zh) 2021-11-22 2023-06-01 美商英塞特公司 包含fgfr抑制劑及kras抑制劑之組合療法
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
EP4444315A1 (en) 2021-12-10 2024-10-16 Eli Lilly and Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
AR128043A1 (es) 2021-12-22 2024-03-20 Incyte Corp Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
TW202341982A (zh) 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Cdk2抑制劑及其用途
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
EP4490151A1 (en) 2022-03-07 2025-01-15 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
HU231594B1 (hu) * 2022-05-10 2025-03-28 Egis Gyógyszergyár Zrt. Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
CN120112291A (zh) 2022-08-31 2025-06-06 阿尔维纳斯运营股份有限公司 雌激素受体降解剂的给药方案
JP2024067010A (ja) 2022-11-02 2024-05-16 ペトラ・ファーマ・コーポレイション 疾患の治療用のホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
CN120344527A (zh) * 2022-12-16 2025-07-18 上海岸阔医药科技有限公司 化合物及其用途
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
US20240390340A1 (en) 2023-04-18 2024-11-28 Incyte Corporation Pyrrolidine kras inhibitors
TW202446371A (zh) 2023-04-18 2024-12-01 美商英塞特公司 2-氮雜雙環[2.2.1]庚烷kras抑制劑
WO2024231275A1 (en) 2023-05-05 2024-11-14 Astrazeneca Ab Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025096738A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
WO2025122470A1 (en) 2023-12-04 2025-06-12 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025129002A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194045A (en) 1979-06-14 1984-09-28 Wellcome Found 6-(2,5-or 3,4-dialkoxybenzyl)-2,4-diamino-5-methylpyrido(2,3-d)pyrimidines
JPS5618982A (en) 1979-06-14 1981-02-23 Wellcome Found Pyrimidine derivatives and medicinal drug containing them
US4959474A (en) 1979-06-14 1990-09-25 Burroughs Wellcome Co. Dialkoxy pyridopyrimidine compounds
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
MD1861G2 (ro) 1994-11-14 2002-09-30 Уорнер-Ламберт Кампэни Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
EP0892795B1 (en) 1996-04-12 2003-01-08 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyramidine derivatives
DE69839338T2 (de) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
KR20010082501A (ko) 1997-10-27 2001-08-30 개리 이. 프라이드만 4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법
WO1999061444A2 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
CA2380389A1 (en) 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
CN1373763A (zh) 1999-09-15 2002-10-09 沃尼尔·朗伯公司 作为激酶抑制剂的蝶啶酮
HUP0203803A3 (en) * 2000-01-27 2004-09-28 Warner Lambert Co Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
HRP20020798A2 (en) * 2000-03-06 2004-02-29 Warner Lambert Co 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS
ES2311532T3 (es) 2000-08-04 2009-02-16 Warner-Lambert Company Llc 2-(4-pirdil)amino-6-dialcoxifenil-pirido(2.3-d)pirimidin-7-onas.
DE60106947T2 (de) 2000-09-01 2005-11-10 Glaxo Group Ltd., Greenford Oxindolderivate
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
HRP20030624B1 (en) * 2001-02-12 2007-03-31 F. Hoffmann - La Roche Ag 6-substituted pyrido-pyrimidines
JP2005524609A (ja) 2001-12-17 2005-08-18 スミスクライン ビーチャム コーポレーション ピラゾロピリダジン誘導体
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
AU2003287178A1 (en) 2002-10-10 2004-05-04 Smithkline Beecham Corporation Chemical compounds
PT1567112E (pt) 2002-11-22 2009-01-08 Smithkline Beecham Corp Novos compostos químicos
US20050009849A1 (en) * 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004065378A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US7507834B2 (en) 2003-02-27 2009-03-24 Smithkline Beechan Corporation Substituted anilinopyrazoles
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
CA2662768A1 (en) 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones

Also Published As

Publication number Publication date
AP1767A (en) 2007-08-13
ECSP105201A (es) 2010-02-26
GEP20063909B (en) 2006-08-25
NO2017014I1 (no) 2017-04-19
HRP20040660B1 (hr) 2012-10-31
AR038814A1 (es) 2005-01-26
FR17C1012I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-07-07
IL162721A0 (en) 2005-11-20
CY2017011I2 (el) 2017-11-14
US20050137214A1 (en) 2005-06-23
LTPA2017013I1 (lt) 2017-05-25
AU2003237009B2 (en) 2008-10-02
BR122016021801B8 (pt) 2021-05-25
AP2004003085A0 (en) 2004-09-30
EA007395B3 (ru) 2018-02-28
DK1470124T3 (da) 2006-04-18
BRPI0307057B8 (pt) 2021-05-25
RS51044B (sr) 2010-10-31
HK1162026A1 (en) 2012-08-17
LUC00009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-05-30
WO2003062236A1 (en) 2003-07-31
MY134818A (en) 2007-12-31
US6936612B2 (en) 2005-08-30
NI200300008A (es) 2004-12-03
DE60303009D1 (de) 2006-02-02
RS59804A (en) 2006-12-15
US7456168B2 (en) 2008-11-25
KR20060111716A (ko) 2006-10-27
SI1470124T1 (sl) 2006-04-30
TWI343920B (en) 2011-06-21
JP4291696B2 (ja) 2009-07-08
IS7323A (is) 2004-06-16
PL218692B1 (pl) 2015-01-30
IS2423B (is) 2008-10-15
BRPI0307057B1 (pt) 2018-05-29
SV2004001459A (es) 2004-07-07
EA200400860A1 (ru) 2004-12-30
JP2005519909A (ja) 2005-07-07
PL372046A1 (en) 2005-07-11
US20030149001A1 (en) 2003-08-07
GT200300005A (es) 2003-08-22
MEP46108A (en) 2011-02-10
CN101001857A (zh) 2007-07-18
CA2473026A1 (en) 2003-07-31
CN102295643A (zh) 2011-12-28
BE2017C005I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-05-17
DE60303009T2 (de) 2006-07-13
UA79444C2 (uk) 2007-06-25
ECSP045201A (es) 2004-08-27
CN101906104A (zh) 2010-12-08
ES2251677T3 (es) 2006-05-01
CY1105686T1 (el) 2010-12-22
CN101906104B (zh) 2013-06-05
MA27166A1 (fr) 2005-01-03
HUS1700019I1 (hu) 2017-05-29
NO20043484L (no) 2004-10-15
NO329350B1 (no) 2010-10-04
USRE47739E1 (en) 2019-11-26
LUC00009I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-03-16
ZA200404840B (en) 2005-09-28
KR20040077759A (ko) 2004-09-06
FR17C1012I2 (fr) 2018-06-08
TNSN04126A1 (fr) 2007-03-12
PA8563701A1 (es) 2003-09-17
IL198243A (en) 2013-05-30
CN102295643B (zh) 2013-12-04
AR083686A2 (es) 2013-03-13
BR122016021801B1 (pt) 2021-02-09
ATE314370T1 (de) 2006-01-15
DOP2003000561A (es) 2003-09-15
CN101001857B (zh) 2011-06-22
EP1470124B1 (en) 2005-12-28
NZ534069A (en) 2007-03-30
HK1146048A1 (en) 2011-05-13
EP1470124A1 (en) 2004-10-27
HN2003000039A (es) 2005-11-12
OA12755A (en) 2006-07-03
LTC1470124I2 (lt) 2019-04-25
HRP20040660A2 (en) 2004-12-31
NO2017014I2 (no) 2017-04-19
HUS1700009I1 (hu) 2017-07-28
NL300863I2 (nl) 2017-08-03
BR0307057A (pt) 2004-10-26
US20070179118A1 (en) 2007-08-02
WO2003062236A8 (en) 2003-12-24
PL391191A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-07-11
PE20030975A1 (es) 2003-11-12
CO5700765A2 (es) 2006-11-30
CA2473026C (en) 2011-05-03
CR20120129A (es) 2012-06-12
UY27617A1 (es) 2003-08-29
US7208489B2 (en) 2007-04-24
CY2017011I1 (el) 2017-11-14
ME00230B (me) 2011-02-10
HK1104296A1 (en) 2008-01-11
IL162721A (en) 2009-12-24
PL220952B1 (pl) 2016-01-29
TW200302224A (en) 2003-08-01
EA007395B1 (ru) 2006-10-27
MXPA04005939A (es) 2005-01-25

Similar Documents

Publication Publication Date Title
KR100669578B1 (ko) 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
US20050182078A1 (en) 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
AU2003237009A1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones
JP2022515335A (ja) 置換ピラゾロ[1,5-a]ピリジン化合物、該化合物を含む組成物およびその使用
KR20240168922A (ko) 방향족 헤테로사이클릭 화합물, 그의 제조 방법 및 그의 용도
KR102731945B1 (ko) 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물
WO2022213980A1 (zh) Tyk2抑制剂及其用途
JP2009073743A (ja) 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物
HK1162026B (en) 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones
HK1146048B (en) 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones
HK1104296B (en) 2-(pyridin-2-ylamino)-pyrido(2,3d)pyrimidin-7-ones
WO2014154026A1 (zh) PI3K和/或mTOR抑制剂的前药
MXPA06009359A (en) 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20040721

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040721

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20051222

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20060713

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20051222

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20060811

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20060713

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20061101

Appeal identifier: 2006101007106

Request date: 20060811

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20060911

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20060911

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20060811

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20060322

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20040721

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20061101

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20061002

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070109

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070108

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20091230

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20101229

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20111228

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20121227

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20121227

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20131227

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20131227

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20141230

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20141230

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20151230

Start annual number: 10

End annual number: 10

PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20161129

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20161229

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20171228

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20191227

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20201224

Start annual number: 15

End annual number: 15

PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 16

End annual number: 16

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 17

End annual number: 17

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 19

End annual number: 19